Gulf Pharmaceutical Industries P.S.C Balance Sheet Health
Financial Health criteria checks 4/6
Gulf Pharmaceutical Industries P.S.C has a total shareholder equity of AED759.9M and total debt of AED921.2M, which brings its debt-to-equity ratio to 121.2%. Its total assets and total liabilities are AED2.4B and AED1.6B respectively. Gulf Pharmaceutical Industries P.S.C's EBIT is AED37.4M making its interest coverage ratio 0.6. It has cash and short-term investments of AED190.0M.
Key information
121.2%
Debt to equity ratio
د.إ921.20m
Debt
| Interest coverage ratio | 0.6x |
| Cash | د.إ190.00m |
| Equity | د.إ759.90m |
| Total liabilities | د.إ1.62b |
| Total assets | د.إ2.38b |
Recent financial health updates
No updates
Recent updates
Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified
Oct 16
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Jan 15Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking
Nov 04Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals
Mar 26Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.
Feb 08Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like
Dec 14Financial Position Analysis
Short Term Liabilities: JULPHAR's short term assets (AED1.5B) exceed its short term liabilities (AED673.3M).
Long Term Liabilities: JULPHAR's short term assets (AED1.5B) exceed its long term liabilities (AED944.1M).
Debt to Equity History and Analysis
Debt Level: JULPHAR's net debt to equity ratio (96.2%) is considered high.
Reducing Debt: JULPHAR's debt to equity ratio has increased from 81.1% to 121.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable JULPHAR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: JULPHAR is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 20.2% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/04 20:42 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gulf Pharmaceutical Industries P.S.C. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null RESEARCH DEPARTMENT | Prime Research |